Yahoo
Shenzhen - Delayed Quote CNY

Huadong Medicine Co., Ltd (000963.SZ)

26.62 +0.74 (+2.86%)
At close: October 30 at 3:04:03 PM GMT+8
Chart Range Bar
Loading chart for 000963.SZ
  • Previous Close 25.88
  • Open 25.80
  • Bid 26.60 x --
  • Ask 26.61 x --
  • Day's Range 25.71 - 26.86
  • 52 Week Range 25.63 - 43.78
  • Volume 26,691,358
  • Avg. Volume 19,119,379
  • Market Cap (intraday) 46.684B
  • Beta (5Y Monthly) 0.00
  • PE Ratio (TTM) 13.58
  • EPS (TTM) 1.96
  • Earnings Date --
  • Forward Dividend & Yield 0.93 (3.49%)
  • Ex-Dividend Date Sep 18, 2026
  • 1y Target Est 36.73

Huadong Medicine Co., Ltd, together with its subsidiaries, engages in the wholesale and retail of pharmaceutical products in China and internationally. The company operates through Pharmaceutical Manufacturing, Pharmaceutical Distribution, Medical Aesthetics, and Industrial Microbiology segments. It offers Chinese medicine, immunosuppressive agents, endocrine, digestive system, antineoplastic, cardiovascular, antibiotic drugs, medical beauty field, and medical devices, as well as engages in pharmaceutical logistics and industrial microbiology activities. In addition, the company provides formulation filling, technical, transportation and warehousing services. The company has strategic collaboration with Heidelberg Pharma AG to jointly develop Antibody Drug Conjugates (ADCs). Huadong Medicine Co., Ltd was incorporated in 1993 and is headquartered in Hangzhou, China.

www.eastchinapharm.com

19,095

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Recent News

View More

Performance Overview

Trailing total returns as of 10/30/2026, which may include dividends or other distributions. Benchmark is SSE Composite Index (000001.SS) .

YTD Return

000963.SZ
30.15%
SSE Composite Index (000001.SS)
9.32%

1-Year Return

000963.SZ
32.03%
SSE Composite Index (000001.SS)
9.73%

3-Year Return

000963.SZ
32.34%
SSE Composite Index (000001.SS)
19.11%

5-Year Return

000963.SZ
19.61%
SSE Composite Index (000001.SS)
1.46%

Earnings Trends

View More

Earnings Per Share (GAAP)

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q3 FY26
Revenue 10.95B
Earnings 911.12M
Profit Margin 8.32%

Q4

FY25

Q1

FY26

Q2

FY26

Q3

FY26

0
2B
4B
6B
8B
10B
0.0%
2.0%
4.0%
6.0%
8.0%

Analyst Insights

View More

Analyst Price Targets

27.10
36.73 Average
26.62 Current
43.53 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Statistics

View More

Valuation Measures

Annual
  • Market Cap

  • Enterprise Value

  • Trailing P/E

  • Forward P/E

  • PEG Ratio (current)

  • Price/Sales (ttm)

  • Price/Book (mrq)

  • Enterprise Value/Revenue

  • Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    7.82%

  • Return on Assets (ttm)

    6.23%

  • Return on Equity (ttm)

    13.52%

  • Revenue (ttm)

    43.97B

  • Net Income Avi to Common (ttm)

    3.44B

  • Diluted EPS (ttm)

    1.96

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    4.11B

  • Total Debt/Equity (mrq)

    7.96%

  • Levered Free Cash Flow (ttm)

    1.96B

Company Insights

Research Reports

View More

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: